Roche Enspryng MOGAD Filing Wins FDA Priority Review as First Potential Treatment for Rare Neuroimmune Disease
The FDA has granted Priority Review to Roche’s Enspryng (satralizumab) for MOGAD, a rare autoimmune CNS disease with no approved treatments, after Phase III METEOROID data showed a 68% relapse risk reduction.
